Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors

Abstract

Immunotherapy, notably chimeric antigen receptor (CAR) modified natural killer (NK) cell therapy, has shown exciting promise in the treatment of hematologic malignancies due to its unique advantages including fewer side effects, diverse activation mechanisms, and wide availability. However, CAR-NK cell therapies have demonstrated limited efficacy against solid tumors, primarily due to challenges posed by the solid tumor microenvironment. In contrast, radiotherapy, a well-established treatment modality, has been proven to modulate the tumor microenvironment and facilitate immune cell infiltration. With these observations, we hypothesize that a novel therapeutic strategy integrating CAR-NK cell therapy with radiotherapy could enhance the ability to treat solid tumors. This hypothesis aims to address the obstacles CAR-NK cell therapies face within the solid tumor microenvironment and explore the potential efficacy of their combination with radiotherapy. By capitalizing on the synergistic advantages of CAR-NK cell therapy and radiotherapy, we posit that this could lead to improved prognoses for patients with solid tumors.

1 Introduction

With the rapid development of immunotherapy in recent years, people have refocused on the impact of the immune system on tumors. Adoptive cell therapy (ACT) is an important treatment approach. The previous ACT involved collecting immune cells from the patient’s body, culturing and expanding them in vitro, and reinjecting them into the body. However, it remains controversial due to its lack of specificity and limited efficacy. With the advancement of genetic engineering technology, researchers have developed an immune cell modified with the chimeric antigen receptor (CAR). This technology involves adding a specific antigen-recognition receptor on the surface of immune cells, which can recognize tumor-specific proteins and greatly enhance the targeting ability of ACT. The classical CAR mainly consists of an antigen-binding domain, a hinge domain, a transmembrane domain, and an intracellular signaling domain. Among them, the antigen-binding domain is composed of the variable region of heavy (VH) and light (VL) chains connected via a flexible linker to form a single-chain fragment variable (scFv) in the extracellular region When the CAR recognizes and binds to the antigen, its intracellular signaling domain sends a signal to activate downstream pathways and stimulate the immune cells to exert their effector functions (1, 2).

The most widely studied approach is CAR-modified T (CAR-T) cell therapy, which has exhibited remarkable efficacy in hematologic malignancies (3) and has been approved by regulatory authorities for treating such tumors. However, it has some drawbacks, including inducing severe cytokine release syndrome and neurotoxicity, a long and expensive production process, and limited therapeutic efficacy on solid tumors (4). As a result, researchers have shifted their attention to NK cells and developed CAR-NK cell therapy as a potential alternative. CAR-NK cells present several advantages over CAR-T cells, such as a lower risk of cytokine release syndrome, absence of graft-versus-host disease (GvHD), and multiple mechanisms of inducing cytotoxicity (5–7). Additionally, NK cells can be extracted from peripheral blood, cord blood, induced pluripotent stem cells, and NK cell lines. In a recent phase I/II clinical trial targeting CD19-positive B-cell lymphoma, CD19-CAR-NK cells exhibited potent anti-tumor effects (8). CAR-NK cells have been observed to have promising therapeutic effects on solid tumors in preclinical studies (9, 10), and corresponding clinical trials are currently underway, but their results have not yet been published. Nevertheless, for an effective CAR-NK cell therapy, it remains a critical challenge to overcome the immunosuppressive property of the solid tumor microenvironment (TME) that hinders the activity and function of NK cells.

Radiation therapy, as a conventional tumor treatment, has recently garnered attention due to its immunomodulatory effects. Increasing evidence suggests that it can reshape the TME and enhance immune cell infiltration (11–13). Several preclinical studies have investigated the combination of CAR-T cell therapy and radiotherapy for treating solid tumors and yielded promising outcomes (Table 1). NK cells, as a component of the innate immune system, possess distinctive activation mechanisms. Their combination with radiotherapy may alter the balance between their activation and inhibition signals, thereby augmenting the NK cell function. The combination of radiation therapy with CAR-NK cell therapy may represent a promising strategy for the treatment of solid tumors. In this review, we will focus on the mechanisms and challenges of this combination therapy.

2 Mechanisms of CAR-NK cell recognizing and killing cancer cells

2.1 Intrinsic mechanism

NK cells are a subset of innate immune cells that lack specific antigen-recognition receptors. They can rapidly recognize and eliminate tumor cells and infected cells without the need for prior sensitization to antigens (18). The activation and regulation of NK cells are determined by a delicate balance between activation and inhibition signals integrated through their surface receptors. Under normal physiological conditions, the inhibitory receptors on NK cells bind to Major Histocompatibility Complex class I molecules (MHC-I) on normal cells to transmit inhibitory signals and put NK cells in an inactive state, thereby preventing normal cells from being killed. However, during tumorigenesis or infection, the downregulation of MHC-I expression in tumor and infected cells disrupts the inhibitory signals, leading to NK cells being activated through a recognition mechanism called “missing-self” (19). Moreover, there are multiple activating receptors on the surface of NK cells, enabling them to recognize and bind to overexpressed or aberrantly expressed proteins on the surface of tumor or infected cells, thereby triggering NK cell activation. The activated NK cells employ diverse mechanisms to directly eliminate target cells, including the release of perforin and granzyme. Moreover, they can induce cell apoptosis through the Fas Ligand/TNF-Related Apoptosis-Inducing Ligand (FasL/TRAIL) signaling pathway or by secreting IFN-γ and TNF-α to engage in receptor-mediated interactions with target cells. Additionally, the Fc receptor CD16 on the surface of NK cells can bind to the Fc region of antibodies and trigger antibody-dependent cell-mediated cytotoxicity (ADCC) to clear target cells (20, 21) (Figure 1).

Figure 1

2.2 CAR-dependent mechanism

During tumor development, tumor cells often downregulate related surface antigens or upregulate some inhibitory receptors to evade immune surveillance, making it difficult for immune cells to recognize the tumor (22). Meanwhile, specific antigens are expressed in certain tumors. These specific antigens can serve as targets for tumor therapy. Installing a chimeric antigen receptor (CAR) structure on immune cells can make them recognize specific antigens. When the CAR binds to the target antigen, the activation signal is transduced into the cell to stimulate NK cell activation and release cytotoxic substances (23) (Figure 1). CAR structures have currently been developed to the fourth generation. The first-generation molecule consists of a synthetic extracellular receptor for antigen recognition, a transmembrane domain, and an intracellular signaling domain. The second and third-generation CAR molecules have one or more intracellular co-stimulatory domains to enhance signal transduction. The fourth-generation CAR, also known as armored CAR, includes molecular payloads that endow CAR-NK cells with additional characteristics and functions. Most CARs used for CAR-NK studies have the same structures as those employed for CAR-T cell therapy because they share the same signal pathways and co-stimulatory domains. However, researchers have developed NK-specific intracellular signaling domains, such as DNAX-activating protein 10 (DAP10), DNAX-activating protein 12 (DAP12), and 2B4, to enhance their cytotoxicity and persistence (24).

Due to the dual cytotoxicity and activation mechanism of CAR-NK cell therapy, it shows greater potential in overcoming the heterogeneity of solid tumors over CAR-T cell therapy and is more effective in combination with radiotherapy for tumor treatment.

3 Challenges encountered by CAR-NK cell therapy in the treatment of solid tumors

3.1 Immune cell homing and transport

Immune cells are usually distributed in the peripheral blood and secondary lymphatic structures of the human body. When the body suffers from infectious or tumor-related diseases, a large number of inflammatory mediators like cytokines and histamines can be released to induce the migration of immune cells to the lesion site through the bloodstream. Then the immune cells adhere to the endothelial cells that line the blood vessels and permeate into the affected tissue via various cascades (25, 26). Nevertheless, solid tumors have abnormal vascular structure and function. Compared with normal blood vessels, their vasculature lacks hierarchical organization and shows a lower expression of adhesion molecules on the endothelium (27, 28), which hinders the migration of immune cells toward tumor tissues. The precise identification of tumors by CAR-NK cells and their successful migration to the tumor core through peripheral blood vessels are crucial prerequisites to ensure the efficacy of immune cell therapy.

3.2 Inhibitory effect of TME on CAR-NK cells

TME refers to the internal environment of tumor development, including tumor cells, immune cells, stromal cells, blood vessels, and extracellular matrix components (29). Abnormal growth of tumor blood vessels can lead to the hypoxic and acidic TME and make NK cells undergo several alterations, including decreased secretion of cytokines, downregulation of activating and death receptors (30), and decreased cytotoxicity. Conversely, lactate and low pH levels can inhibit the activity of NK cells and the IFNγ release (31). TME also releases various cytokines that suppress NK cell activity, such as prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO), extracellular adenosine, transforming growth factor β (TGF-β), and soluble MICA (sMICA) (32). Among these factors, TGF-β can significantly diminish the expression levels of activating receptors NKG2D and NKp30 on the NK cell surface (33). It can further disrupt IFN-γ generation and inhibit its differentiation into type 1 innate-like lymphoid cells (ILC1) (34, 35), thereby impairing the NK cell cytotoxicity. TME has diverse immunosuppressive cells, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), all of which hinder NK cell activity. Tregs can inhibit NK cell activity by interacting with membrane-bound protein TGF-β and secreting TGF-β and IL-10 (36). Furthermore, Tregs compete with NK cells to bind IL-2 and suppress NK cell activation (37). MDSCs can impede NK cell-mediated ADCC via the release of nitric oxide (NO) (38). These cytokines and immunosuppressive cells do not act independently but function in a complex interaction.

4 Current status of CAR-NK cell therapy in the treatment of solid tumors

The currently available data on the efficacy of CAR-NK cell therapy primarily comes from hematologic malignancies. It has shown anti-tumor activity in various preclinical models of solid tumors (9, 39–42), including ovarian cancer, glioblastoma, pancreatic cancer, breast cancer, lung cancer, and others. Moreover, several CAR-NK cell therapies have been approved for treating certain cancers based on their promising performance in phase I/II clinical trials. Common target antigens include PSMA, ROBO1, and NKG2D, although their specific data has not been publicly disclosed. Currently, 13 clinical trials of CAR-NK cell therapy for solid tumors have been registered on ClinicalTrials.gov (Table 2).

5 Principle of CAR-NK cell therapy combined with radiotherapy

Radiotherapy, as the cornerstone of cancer treatment, exerts its effects by releasing high-energy radiation that directly or indirectly damages cellular DNA (43–45). In addition to direct cytotoxicity towards tumor cells, it can induce a series of biological responses that have profound impacts on the immune system and TME.

In 1953, Mole proposed the abscopal effect (46), which refers to the phenomenon where non-irradiated tumor lesions shrink in addition to the irradiated tumor lesions. This phenomenon is extremely rare and unpredictable. Subsequent researchers found that, in immune-deficient mouse tumor models, the radiation dose required to achieve tumor control was often higher than that in immune-competent mice (47), suggesting that the immune system contributes to enhancing the efficacy of radiotherapy. However, this did not receive much attention at the time. It was not until 2004 that Demaria et al. (48) confirmed that the abscopal effect induced by radiotherapy is mediated by the immune system. With the continuous progress of preclinical studies, more and more mechanisms have been discovered. Firstly, radiotherapy can induce immunogenic cell death (ICD) in tumor cells, leading to the release of damage-associated molecular patterns (DAMPs) (49–51). The primary components of DAMPs include: 1. The translocation of calreticulin from the endoplasmic reticulum to the cell membrane, which activates the antigen presentation function of dendritic cells (DCs), At the same time, calreticulin can also be recognized by the NKp46 receptor of NK cells, enhancing the cytotoxicity of NK cells (52–54). 2. The release of adenosine triphosphate (ATP), which recruits DC cells, macrophages, T cells, B cells, etc., to migrate to the injury site, releases inflammatory factors, and initiates adaptive immune responses (55). 3. The release of high mobility group protein B1 (HMGB1) promotes the maturation of dendritic cells, and then activates T cells (56). On the other hand, radiotherapy can alter the phenotype of tumor cells, leading to the upregulation of cell surface molecules and increasing the presentation of antigens, making the tumor cells more susceptible to immune cell attacks (57, 58). Lastly, radiotherapy can lead to the exposure of dsDNA, which is recognized and bound by cyclic GMP-AMP synthase (cGAS), and stimulates the production of many immune and inflammatory gene products, such as Type I interferons, through the cGAS/STING signaling pathway (59, 60). These pro-inflammatory factors recruit immune cells into the tumor, thereby remolding the tumor microenvironment and converting “cold” tumors with less immune cell infiltration into “hot” tumors with immune cell infiltration (Figure 2). Though preclinical studies illustrate the mechanisms of radiotherapy-induced abscopal effects, observation of these effects in clinical practice remains a rarity when radiotherapy is administered in isolation. This scarcity may be ascribable to the inability of radiotherapy alone to adequately surmount the cancer-induced immunosuppression.

Figure 2

With the emergence of immunotherapy, immune checkpoint inhibitors have been approved for clinical use, and an increasing number of abscopal effect cases have been reported. The first report came from a melanoma patient who experienced disease progression during a clinical trial of ipilimumab, but subsequently experienced tumor reduction outside of the irradiated field following radiotherapy (61). Meanwhile, a retrospective analysis of 24 cases confirmed that abscopal effects are more common in patients receiving combined radiotherapy and immunotherapy (62). The impact of radiotherapy on the immune system has regained attention. Researchers have begun to explore combinations of radiotherapy with various immunotherapies, including immune checkpoint inhibitors, adoptive cell therapy, cytokine therapy, etc. Currently, there are over hundreds of ongoing clinical trials combining radiotherapy with different immunotherapies.

It is generally believed that radiotherapy-induced antitumor immune responses are primarily mediated by T cells. A large body of research has also confirmed the crucial role of T cells in radiotherapy-induced immune responses (48, 63, 64). However, with the development of immunology, researchers have begun to pay attention to the role of NK cells in this process. We will subsequently introduce the role of NK cells in radiotherapy-induced antitumor immunity, as well as the potential mechanism of combining CAR-NK with radiotherapy.

5.1 Radiotherapy enhancing NK cell homing and transport

Compared with normal blood vessels, tumor blood vessels exhibit immature morphology, irregular distribution, and increased permeability. The effects of radiation therapy on tumor vasculature vary greatly and depend on several factors like radiation dose, fractionation schedule, tumor type, and tumor location. Typically, a single high dose exceeding 10 Gy can cause endothelial cell death, acute vascular injury, reduced blood perfusion, and cell hypoxia within hours (65). However, moderate to low doses can stimulate vascular regeneration and induce vascular normalization. Studies have reported that a radiation dose ranging from 5-10 Gy can transiently restore normal vascular function by inducing NO release and lead to tumor reoxygenation, improved blood flow, and increased tumor perfusion (66). Notably, Ganss et al. demonstrated that irradiation of the RIP1-Tag5 mice of pancreatic islet tumor with a dose of 10 Gy could normalize tumor blood vessels and enhance lymphocyte infiltration into the tumor (67). Similarly, Potiron et al. found that a fractionated radiation regimen (2 Gy per fraction, 5 fractions per week, a total dose of 20 Gy in 10 fractions) could improve tumor vascular maturity and perfusion and reduce cell hypoxia in a prostate cancer xenograft model, and it did not alter the tumor vascular morphology or density (68). Subsequent experiments have confirmed that low-dose radiation therapy can normalize tumor vasculature and enhance drug distribution within the tumor (69). Additionally, radiation therapy can increase the expression of adhesion molecules like intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on tumor endothelial cells (70, 71). These adhesion molecules facilitate the adherence of NK cells to the endothelial cells and promote extravasation into the tumor. Based on these findings, the combination of radiation therapy with CAR-NK cell therapy may enhance CAR-NK cell homing and delivery, and the vascular normalization induced by radiation therapy may reverse the inhibitory effect of hypoxia on CAR-NK cells.

5.2 Radiotherapy increasing NK cell infiltration and recognition

The infiltration degree of NK cells in tumor tissues is often positively correlated with the patient’s prognosis (72–74). Radiotherapy plays a crucial role in NK cell migration and infiltration. A study on single-cell sequencing of the paired cervical cancer samples before and after radiochemotherapy revealed a substantially increased number of CD16-NK cells in tumor tissues following treatment. Analysis of the transcriptome data on infiltrating NK cells after radiochemotherapy demonstrated an increased expression of genes associated with leukocyte migration and cytotoxicity (75). Similar results were obtained in endometrial cancer and colorectal cancer, where radiotherapy increased NK cell infiltration (76, 77). The influence of radiotherapy on NK cell migration may be attributed to the regulation of several chemokines. NK cells have many chemokine receptor proteins on their surface, such as CXCR1, CXCR2, CXCR3, CXCR6, and CCR5. These receptors facilitate the tumor cells’ perception of signal gradients of specific chemokines and guide their migration process. Moreover, radiotherapy can induce DNA damage, activate the cGAS/STING signaling pathway, trigger a type I interferon response, and promote the production of some cytokines like CXCL9, CXCL10, and CXCL11 (78–80). These cytokines bind to receptors on NK cells and enhance immune cell migration and infiltration into the tumor site (81).In addition, radiotherapy-induced production of CXCL8 with CXCL16 has been reported to be associated with NK cell migration and infiltration (82, 83).

Radiotherapy can induce the secretion of multiple chemokines, upregulate the expression of tumor-specific surface antigens, and enhance the recognition and activation of NK cells. Research has demonstrated that radiotherapy at a dose of 20 Gy can increase the expression of MICA/B and ULBP1/2 on the surface of tumor cells, and, co-culture with these tumor cells can enhance the cytotoxicity of NK cells (84). Another study analyzed the paired samples from sarcoma patients before and after radiotherapy; the post-radiotherapy tumor cells exhibited stem cell characteristics and an upregulated expression of MICA/B, making them more susceptible to NK cell-mediated cytotoxicity (85). Moreover, radiotherapy upregulates the expression of ICAM1 on cell surface, promotes the adhesion between NK and tumor cells, and enhances NK cell-mediated toxicity (86).The radiotherapy combined with adoptive NK cell therapy could significantly prolong overall survival and suppress lymph node metastasis and distant metastasis in a mouse model of triple-negative breast cancer. Besides, radiotherapy and adoptive NK cell therapy showed favorable results in canine sarcoma models by enhancing NK cell homing and NK cell-mediated cytotoxicity (87, 88).

In conclusion, these preclinical studies show that radiotherapy can enhance the infiltration ability and tumor recognition ability of NK cells in adoptive therapy (Table 3).

5.3 Radiation therapy reducing tumor burden and heterogeneity

Solid tumors often display significant heterogeneity, which can lead to antigen escape during CAR-NK cell therapy. Radiotherapy can effectively kill a substantial number of tumor cells and reduce tumor heterogeneity. Furthermore, it can decrease tumor burden and create a more favorable environment for immune cell infiltration. Previous literature has reported that patients with lower tumor burdens have better response rates and outcomes to CAR-T cell therapy (90).

6 Challenges faced by the combination therapy

6.1 Radiotherapy-mediated immunosuppression

Although radiotherapy and adoptive NK cell therapy have shown promising synergistic effects in clinical or preclinical experiments, the immunosuppressive effects brought by radiotherapy cannot be ignored. Radiotherapy can directly exert cytotoxic effects on immune cells. Several studies have reported reduced number and activity of NK cells in patients following radiotherapy (91, 92), indicating that NK cell therapy should be administered after radiotherapy and highlighting the significance of its initiation timing in combination treatment. Moreover, radiotherapy can recruit immunosuppressive cells from TME, such as Tregs and MDSCs. Numerous studies have shown a significantly increased number of intratumoral Tregs after radiotherapy (93–95), while Tregs can exert strong inhibitory effects on NK cells (96). The precise mechanism of radiotherapy-induced expansion of Tregs has not yet been fully elucidated. Recent research has revealed that radiotherapy at a dose of 10 Gy prioritizes stimulating proliferation of pre-existing intratumoral Tregs, rather than recruiting peripheral blood Tregs into the tumor, and this study further revealed that TGFβ and IL33 signaling pathways were irrelevant to Treg expansion (93). Furthermore, a study on a mouse model of head and neck squamous cell carcinoma demonstrated that high-dose radiotherapy induced tumor cells to secrete the chemokine CCL20, which could enhance Tregs to infiltrate into the tumor tissue via the CCR6-CCL20 axis and exert their immunosuppressive effects (97). These studies indicate that radiotherapy-induced infiltration of Tregs into tumors may involve various factors, including tumor type, radiation dose, and fractionation schedule. The effectiveness of radiotherapy combined with targeted inhibitors against Tregs has been confirmed in some preclinical studies (98). Radiation therapy can induce the release of chemokine CCL2 to recruit MDSCs, while CCL2 can activate the CCL2/CCR2 and CCL2/CCR5 signaling pathways, leading to MDSCs infiltration into the TME and immune suppression (99–101). Moreover, radiation therapy can modulate the expression of tumor-associated antigens like MHC class I molecules (58, 102), decrease the NK cell’s ability to recognize the tumor. Therefore, it is crucial to address the immunosuppressive effects induced by radiation therapy and maximize the synergistic effects of radiotherapy and CAR-NK cell therapy. Further experiments are warranted to gain deeper insights into the complex interaction between radiation therapy and immunotherapy.

6.2 Optimal radiotherapy dose and fractionation scheme

There is a lack of clinical and preclinical data supporting the therapeutic efficacy of the combination of radiotherapy with CAR-NK cell therapy, and the optimal dosage and schedule of radiotherapy remain unclear. A critical issue is whether higher ablative doses or lower doses of radiotherapy can yield better outcomes in combination therapy. Furthermore, different cancers may exhibit distinct responses to the combination therapy. The higher ablative doses of radiotherapy may promote ICD, release DAMPs, and activate immune cells (103). Nevertheless, its low dose may reverse tumor immune desertification and increase the infiltration of immune cells into tumors (104).

Numerous studies have shown an increased infiltration of NK cells into tumor tissues after administering standard radiation doses of 50-60 Gy (75, 77, 105). A preclinical investigation aimed to explore the impact of dose per fraction (DPF) and cumulative dose on the immunomodulatory capability of radiotherapy. Utilizing an AT3-OVA mouse model, it was observed that lower DPFs (3x4 Gy, 9x4 Gy, 3x8 Gy) could significantly stimulate CD8+ T cell-mediated antitumor activity compared with a single administration of a high dose fraction (1x12 Gy, 1x20 Gy). Conversely, the activation of NK cell-mediated antitumor function was found to be dependent on the cumulative dose rather than the DPF, and its remarkable enhancement was observed after surpassing a biologically effective dose of 36 Gy. These findings strongly suggest the application of conventional radiotherapy doses in combination with CAR-NK cell therapy (106). A dose threshold exceeding 7.5 Gy in the single high-dose radiation therapy has been shown to increase Treg infiltration and lead to immune suppression. Therefore, it is advised to set the radiotherapy dose below this threshold to optimize treatment outcomes and minimize immunosuppressive effects (107). Further research is required to determine the most effective dosage and fractionation schedule of radiotherapy in combination with CAR-NK cell therapy. The existing evidence suggests that ablative high-dose and low-dose radiotherapy have advantages in immunogenicity and immune activation, but their efficacies may vary depending on the specific cancer model.

6.3 Therapeutic sequence

Radiation is commonly regarded as detrimental to NK cells, leading to apoptosis and dysfunction of these cells (108). Therefore, it is recommended that radiotherapy be administered prior to CAR-NK cell infusion to prevent direct damage to the NK cells. In recent years, advancements in radiotherapy technology have allowed for greater precision in dose delivery, minimizing damage to surrounding blood vessels, lymph nodes, and normal tissues, and subsequently reducing the impact on immune cells (109). However, the timing of radiotherapy intervention within the context of combination therapy remains a critical factor. Min Zhou et al. (14) conducted a study exploring the optimal timing of radiotherapy intervention in a breast cancer mouse model treated with a CAR-T cell therapy and radiotherapy combination. Their results showed no statistically significant differences in tumor volume control and survival of mice when administering radiotherapy before or after infusion. This research is the sole study investigating the treatment sequence of adoptive immunotherapy in combination with radiotherapy.

According to previous studies, the post-radiotherapy administration of CAR-NK cells appears to be an effective approach for several reasons. Firstly, the lymphopenia resulting from radiotherapy may cultivate an optimal milieu for the proliferation of the introduced CAR-NK cells. similar to the pretreatment before CAR-T infusion (110, 111). Furthermore, lasting chemokine release is precipitated by radiotherapy enhancing the chemotaxis of these immune cell (82, 83). Also, radiotherapy mediates a significant reduction in tumoral burden, thereby improving the potential for efficient tumoral infiltration by the subsequent CAR-NK cell administration. Overall, these findings are more supportive of using CAR-NK after radiotherapy. Notably, research has indicated that a single low dose of radiation (<2Gy) can enhance the expansion and cytokine secretion function of NK cells in vitro (112, 113). Simultaneously, low-dose radiation therapy in a mouse model has been shown to increase the cytotoxic function of NK cells, consequently inhibiting the growth of experimental tumor (114, 115). Due to the limited duration of CAR-NK cells in the body (8), multiple injections are required to maintain therapeutic efficacy. The application of low-dose radiotherapy following CAR-NK cell infusion may represent a potential strategy for bolstering the functionality and durability of CAR-NK cells. Additional research and thorough investigation are crucial to validate the effectiveness of this potential therapeutic strategy (Figure 3).

Figure 3

7 Discussion

Based on the aforementioned preclinical research findings, a theoretical basis is provided for the combined therapy of NK cells and radiotherapy. A phase II randomized controlled trial reported favorable results from the use of autologous NK cell adoptive therapy following chemo-radiotherapy in non-small cell lung cancer (116). At present, multiple clinical trials using non-engineered NK cells combined with therapies for solid tumors, including chemo-radiotherapy, immune checkpoint inhibitors, and targeted therapies, are under way. Furthermore, an increasing number of researchers are beginning to use engineered NK cells for combination therapy. Apart from endowing NK cells with innate cytotoxicity, engineered NK cells have been given additional functionalities, potentially increasing their effectiveness in combined therapy. Though clinical data for CAR-NK therapy of solid tumors have yet to be published, and clinical trials combining it with radiotherapy have not started, we hold an optimistic view of the potential of this combination therapy. Firstly, in the case of solid tumors such as glioblastoma, pancreas and ovarian cancer, they are usually diagnosed at a late stage and generally show resistance to existing treatments, with almost no current targeted treatment options. CAR-NK cells may demonstrate a synergistic effect with standard treatments (chemotherapy, radiotherapy, targeted therapies), offering a possible treatment option for late-stage patients. The aim is to improve the targeting, endurance, chemotaxis, and safety of CAR-NK cells. current development strategies for CAR-NK therapy in solid tumors focus on identifying reliable new targets and constructing dual-targeted or multi-targeted CAR structures to enhance targeting, durability, chemotaxis, and safety. The increased exposure of neoantigens and expression of chemokines in tumor cells induced by radiotherapy may offer new avenues for CAR-NK therapy development, such as CARs targeting NKG2DL or overexpressing chemokine receptors (CXCR1, CXCR2, and CXCR4) through CAR design (117–120).

8 Conclusion

In summary, this article reviews the role and latest advancements of NK cells in radiotherapy-induced anti-tumor immunity. On the basis of this evidence, we propose that a combination of CAR-NK cell therapy and radiotherapy may be a method to overcome solid tumors. This hypothesis could provide treatment options for patients with advanced solid tumors and also offer strategies for the development of CAR-NK. However, to determine the optimal radiation dosage, fractionation scheme, and order of administration, a substantial amount of preclinical and clinical experiments is still necessary. Moreover, identifying specific biomarkers is crucial for selecting appropriate patients and minimizing potential treatment-related toxicity to the maximum extent.

References

• 1

  LarsonRCMausMV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer (2021) 21(3):145–61. doi: 10.1038/s41568-020-00323-z

  • CrossRef
  • Google Scholar

• 2

  JuneCHSadelainM. Chimeric antigen receptor therapy. N Engl J Med (2018) 379(1):64–73. doi: 10.1056/NEJMra1706169

  • CrossRef
  • Google Scholar

• 3

  NeelapuSSLockeFLBartlettNLLekakisLJMiklosDBJacobsonCAet al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med (2017) 377(26):2531–44. doi: 10.1056/NEJMoa1707447

  • CrossRef
  • Google Scholar

• 4

  Shimabukuro-VornhagenABollBSchellongowskiPValadeSMetaxaVAzoulayEet al. Critical care management of chimeric antigen receptor T-cell therapy recipients. CA Cancer J Clin (2022) 72(1):78–93. doi: 10.3322/caac.21702

  • CrossRef
  • Google Scholar

• 5

  LongEOKimHSLiuDPetersonMERajagopalanS. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol (2013) 31:227–58. doi: 10.1146/annurev-immunol-020711-075005

  • CrossRef
  • Google Scholar

• 6

  ZhangCHuYXiaoWTianZ. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. Cell Mol Immunol (2021) 18(9):2083–100. doi: 10.1038/s41423-021-00732-6

  • CrossRef
  • Google Scholar

• 7

  OlsonJALeveson-GowerDBGillSBakerJBeilhackANegrinRS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood (2010) 115(21):4293–301. doi: 10.1182/blood-2009-05-222190

  • CrossRef
  • Google Scholar

• 8

  LiuEMarinDBanerjeePMacapinlacHAThompsonPBasarRet al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med (2020) 382(6):545–53. doi: 10.1056/NEJMoa1910607

  • CrossRef
  • Google Scholar

• 9

  LiuMHuangWGuoYZhouYZhiCChenJet al. CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo. J Leukoc Biol (2022) 112(4):901–11. doi: 10.1002/JLB.5MA0122-467R

  • CrossRef
  • Google Scholar

• 10

  HanJChuJKeung ChanWZhangJWangYCohenJBet al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep (2015) 5:11483. doi: 10.1038/srep11483

  • CrossRef
  • Google Scholar

• 11

  WeichselbaumRRLiangHDengLFuYX. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol (2017) 14(6):365–79. doi: 10.1038/nrclinonc.2016.211

  • CrossRef
  • Google Scholar

• 12

  McLaughlinMPatinECPedersenMWilkinsADillonMTMelcherAAet al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer (2020) 20(4):203–17. doi: 10.1038/s41568-020-0246-1

  • CrossRef
  • Google Scholar

• 13

  ZhangZLiuXChenDYuJ. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther (2022) 7(1):258. doi: 10.1038/s41392-022-01102-y

  • CrossRef
  • Google Scholar

• 14

  ZhouMChenMShiBDiSSunRJiangHet al. Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-kappaB/Icam1 signaling. Mol Ther (2022) 30(11):3379–93. doi: 10.1016/j.ymthe.2022.07.021

  • CrossRef
  • Google Scholar

• 15

  WeissTWellerMGuckenbergerMSentmanCLRothP. NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res (2018) 78(4):1031–43. doi: 10.1158/0008-5472.CAN-17-1788

  • CrossRef
  • Google Scholar

• 16

  MurtySHaileSTBeinatCAalipourAAlamISMurtyTet al. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model. Oncoimmunology (2020) 9(1):1757360. doi: 10.1080/2162402X.2020.1757360

  • CrossRef
  • Google Scholar

• 17

  DeSelmCPalombaMLYahalomJHamiehMEyquemJRajasekharVKet al. Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol Ther (2018) 26(11):2542–52. doi: 10.1016/j.ymthe.2018.09.008

  • CrossRef
  • Google Scholar

• 18

  FangFXiaoWTianZ. Challenges of NK cell-based immunotherapy in the new era. Front Med (2018) 12(4):440–50. doi: 10.1007/s11684-018-0653-9

  • CrossRef
  • Google Scholar

• 19

  LjunggrenHGKarreK. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today (1990) 11(7):237–44. doi: 10.1016/0167-5699(90)90097-S

  • CrossRef
  • Google Scholar

• 20

  ZittiBBrycesonYT. Natural killer cells in inflammation and autoimmunity. Cytokine Growth Factor Rev (2018) 42:37–46. doi: 10.1016/j.cytogfr.2018.08.001

  • CrossRef
  • Google Scholar

• 21

  LanierLL. NK cell recognition. Annu Rev Immunol (2005) 23:225–74. doi: 10.1146/annurev.immunol.23.021704.115526

  • CrossRef
  • Google Scholar

• 22

  WuSYFuTJiangYZShaoZM. Natural killer cells in cancer biology and therapy. Mol Cancer (2020) 19(1):120. doi: 10.1158/1557-3125.HIPPO19-IA12

  • CrossRef
  • Google Scholar

• 23

  XieGDongHLiangYHamJDRizwanRChenJ. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine (2020) 59:102975. doi: 10.1016/j.ebiom.2020.102975

  • CrossRef
  • Google Scholar

• 24

  DaherMRezvaniK. Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer. Cancer Discov (2021) 11(1):45–58. doi: 10.1158/2159-8290.CD-20-0556

  • CrossRef
  • Google Scholar

• 25

  AlcaideP. Mechanisms regulating T cell-endothelial cell interactions. Cold Spring Harb Perspect Med (2022) 12(7):a041170. doi: 10.1101/cshperspect.a041170

  • CrossRef
  • Google Scholar

• 26

  SchnoorMAlcaidePVoisinMBvan BuulJD. Crossing the vascular wall: common and unique mechanisms exploited by different leukocyte subsets during extravasation. Mediators Inflamm (2015) 2015:946509. doi: 10.1155/2015/946509

  • CrossRef
  • Google Scholar

• 27

  SchmidtJRyschichEMaksanSMWernerJGebhardMMHerfarthCet al. Reduced basal and stimulated leukocyte adherence in tumor endothelium of experimental pancreatic cancer. Int J Pancreatol (1999) 26(3):173–9. doi: 10.1385/IJGC:26:3:173

  • CrossRef
  • Google Scholar

• 28

  SchmidtJRyschichEDanielVHerzogLWernerJHerfarthCet al. Vascular structure and microcirculation of experimental pancreatic carcinoma in rats. Eur J Surg (2000) 166(4):328–35. doi: 10.1080/110241500750009195

  • CrossRef
  • Google Scholar

• 29

  AndersonNMSimonMC. The tumor microenvironment. Curr Biol (2020) 30(16):R921–R5. doi: 10.1016/j.cub.2020.06.081

  • CrossRef
  • Google Scholar

• 30

  ParodiMRaggiFCangelosiDManziniCBalsamoMBlengioFet al. Hypoxia modifies the transcriptome of human NK cells, modulates their immunoregulatory profile, and influences NK cell subset migration. Front Immunol (2018) 9:2358. doi: 10.3389/fimmu.2018.02358

  • CrossRef
  • Google Scholar

• 31

  TerrenIOrrantiaAVitalleJZenarruzabeitiaOBorregoF. NK cell metabolism and tumor microenvironment. Front Immunol (2019) 10:2278. doi: 10.3389/fimmu.2019.02278

  • CrossRef
  • Google Scholar

• 32

  VitaleMCantoniCPietraGMingariMCMorettaL. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol (2014) 44(6):1582–92. doi: 10.1002/eji.201344272

  • CrossRef
  • Google Scholar

• 33

  CastriconiRCantoniCDella ChiesaMVitaleMMarcenaroEConteRet al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA (2003) 100(7):4120–5. doi: 10.1073/pnas.0730640100

  • CrossRef
  • Google Scholar

• 34

  YuJWeiMBecknellBTrottaRLiuSBoydZet al. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity (2006) 24(5):575–90. doi: 10.1016/j.immuni.2006.03.016

  • CrossRef
  • Google Scholar

• 35

  RegisSDonderoACaliendoFBottinoCCastriconiR. NK cell function regulation by TGF-beta-induced epigenetic mechanisms. Front Immunol (2020) 11:311. doi: 10.3389/fimmu.2020.00311

  • CrossRef
  • Google Scholar

• 36

  GhiringhelliFMenardCTermeMFlamentCTaiebJChaputNet al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 202(8):1075–85. doi: 10.1084/jem.20051511

  • CrossRef
  • Google Scholar

• 37

  GhiringhelliFMenardCMartinFZitvogelL. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev (2006) 214:229–38. doi: 10.1111/j.1600-065X.2006.00445.x

  • CrossRef
  • Google Scholar

• 38

  StiffATrikhaPMundy-BosseBMcMichaelEMaceTABennerBet al. Nitric oxide production by myeloid-derived suppressor cells plays a role in impairing fc receptor-mediated natural killer cell function. Clin Cancer Res (2018) 24(8):1891–904. doi: 10.1158/1078-0432.CCR-17-0691

  • CrossRef
  • Google Scholar

• 39

  BarkerHEPagetJTKhanAAHarringtonKJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer (2015) 15(7):409–25. doi: 10.1038/nrc3958

  • CrossRef
  • Google Scholar

• 40

  ChangYHConnollyJShimasakiNMimuraKKonoKCampanaD. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res (2013) 73(6):1777–86. doi: 10.1158/0008-5472.CAN-12-3558

  • CrossRef
  • Google Scholar

• 41

  SchonfeldKSahmCZhangCNaundorfSBrendelCOdendahlMet al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther (2015) 23(2):330–8. doi: 10.1038/mt.2014.219

  • CrossRef
  • Google Scholar

• 42

  TopferKCartellieriMMichenSWiedemuthRMullerNLindemannDet al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol (2015) 194(7):3201–12. doi: 10.4049/jimmunol.1400330

  • CrossRef
  • Google Scholar

• 43

  ErikssonDStigbrandT. Radiation-induced cell death mechanisms. Tumour Biol (2010) 31(4):363–72. doi: 10.1007/s13277-010-0042-8

  • CrossRef
  • Google Scholar

• 44

  AzzamEIJay-GerinJPPainD. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. Cancer Lett (2012) 327(1-2):48–60. doi: 10.1016/j.canlet.2011.12.012

  • CrossRef
  • Google Scholar

• 45

  ReiszJABansalNQianJZhaoWFurduiCM. Effects of ionizing radiation on biological molecules–mechanisms of damage and emerging methods of detection. Antioxid Redox Signal (2014) 21(2):260–92. doi: 10.1089/ars.2013.5489

  • CrossRef
  • Google Scholar

• 46

  MoleRH. Whole body irradiation; radiobiology or medicine? Br J Radiol (1953) 26(305):234–41. doi: 10.1259/0007-1285-26-305-234

  • CrossRef
  • Google Scholar

• 47

  StoneHBPetersLMilasL. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Nati Cancer Inst (1979) 63(5):1229–35.

  • Google Scholar

• 48

  DemariaSNgBDevittMLBabbJSKawashimaNLiebesLet al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 58(3):862–70. doi: 10.1016/j.ijrobp.2003.09.012

  • CrossRef
  • Google Scholar

• 49

  KroemerGGalluzziLKeppOZitvogelL. Immunogenic cell death in cancer therapy. Annu Rev Immunol (2013) 31:51–72. doi: 10.1146/annurev-immunol-032712-100008

  • CrossRef
  • Google Scholar

• 50

  GalluzziLBuqueAKeppOZitvogelLKroemerG. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol (2017) 17(2):97–111. doi: 10.1038/nri.2016.107

  • CrossRef
  • Google Scholar

• 51

  GoldenEBFrancesDPellicciottaIDemariaSHelen Barcellos-HoffMFormentiSC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology (2014) 3:e28518. doi: 10.4161/onci.28518

  • CrossRef
  • Google Scholar

• 52

  ObeidMTesniereAGhiringhelliFFimiaGMApetohLPerfettiniJLet al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2007) 13(1):54–61. doi: 10.1038/nm1523

  • CrossRef
  • Google Scholar

• 53

  Sen SantaraSLeeDJCrespoAHuJJWalkerCMaXet al. The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Nature (2023) 616(7956):348–56. doi: 10.1038/s41586-023-05912-0

  • CrossRef
  • Google Scholar

• 54

  FucikovaJSpisekRKroemerGGalluzziL. Calreticulin and cancer. Cell Res (2021) 31(1):5–16. doi: 10.1038/s41422-020-0383-9

  • CrossRef
  • Google Scholar

• 55

  MichaudMMartinsISukkurwalaAQAdjemianSMaYPellegattiPet al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 334(6062):1573–7. doi: 10.1126/science.1208347

  • CrossRef
  • Google Scholar

• 56

  ChenRKangRTangD. The mechanism of HMGB1 secretion and release. Exp Mol Med (2022) 54(2):91–102. doi: 10.1038/s12276-022-00736-w

  • CrossRef
  • Google Scholar

• 57

  HellstromKEHellstromIKantJATameriusJD. Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population. J Exp Med (1978) 148(3):799–804. doi: 10.1084/jem.148.3.799

  • CrossRef
  • Google Scholar

• 58

  ReitsEAHodgeJWHerbertsCAGroothuisTAChakrabortyMWansleyEKet al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 203(5):1259–71. doi: 10.1084/jem.20052494

  • CrossRef
  • Google Scholar

• 59

  WooSRFuertesMBCorralesLSprangerSFurdynaMJLeungMYet al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity (2014) 41(5):830–42. doi: 10.1016/j.immuni.2014.10.017

  • CrossRef
  • Google Scholar

• 60

  BarberGN. STING-dependent cytosolic DNA sensing pathways. Trends Immunol (2014) 35(2):88–93. doi: 10.1016/j.it.2013.10.010

  • CrossRef
  • Google Scholar

• 61

  PostowMACallahanMKBarkerCAYamadaYYuanJKitanoSet al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 366(10):925–31. doi: 10.1056/NEJMoa1112824

  • CrossRef
  • Google Scholar

• 62

  DagogluNKaramanSCaglarHBOralEN. Abscopal effect of radiotherapy in the immunotherapy era: systematic review of reported cases. Cureus (2019) 11(2):e4103. doi: 10.7759/cureus.4103

  • CrossRef
  • Google Scholar

• 63

  ChakrabortyMAbramsSIColemanCNCamphausenKSchlomJHodgeJW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res (2004) 64(12):4328–37. doi: 10.1158/0008-5472.CAN-04-0073

  • CrossRef
  • Google Scholar

• 64

  LimJYGerberSAMurphySPLordEM. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother (2014) 63(3):259–71. doi: 10.1007/s00262-013-1506-7

  • CrossRef
  • Google Scholar

• 65

  SongCWLeeYJGriffinRJParkIKoonceNAHuiSet al. Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int J Radiat Oncol Biol Phys (2015) 93(1):166–72. doi: 10.1016/j.ijrobp.2015.05.016

  • CrossRef
  • Google Scholar

• 66

  SonveauxPBrouetAHavauxXGrégoireVDessyCBalligandJLet al. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res (2003) 63(5):1012–9.

  • Google Scholar

• 67

  GanssRRyschichEKlarEArnoldBHämmerlingGJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res (2002) 62(5):1462–70.

  • Google Scholar

• 68

  PotironVAAbderrahmaniRClement-ColmouKMarionneau-LambotSOullierTParisFet al. Improved functionality of the vasculature during conventionally fractionated radiation therapy of prostate cancer. PloS One (2013) 8(12):e84076. doi: 10.1371/journal.pone.0084076

  • CrossRef
  • Google Scholar

• 69

  PotironVClement-ColmouKJouglarEPietriMChiavassaSDelponGet al. Tumor vasculature remodeling by radiation therapy increases doxorubicin distribution and efficacy. Cancer Lett (2019) 457:1–9. doi: 10.1016/j.canlet.2019.05.005

  • CrossRef
  • Google Scholar

• 70

  LugadeAASorensenEWGerberSAMoranJPFrelingerJGLordEM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol (2008) 180(5):3132–9. doi: 10.4049/jimmunol.180.5.3132

  • CrossRef
  • Google Scholar

• 71

  BehrendsUPeterRUHintermeier-KnabeREissnerGHollerEBornkammGWet al. Ionizing radiation induces human intercellular adhesion molecule-1 in vitro. J Invest Dermatol (1994) 103(5):726–30. doi: 10.1111/1523-1747.ep12398607

  • CrossRef
  • Google Scholar

• 72

  CozarBGreppiMCarpentierSNarni-MancinelliEChiossoneLVivierE. Tumor-infiltrating natural killer cells. Cancer Discov (2021) 11(1):34–44. doi: 10.1158/2159-8290.CD-20-0655

  • CrossRef
  • Google Scholar

• 73

  NersesianSSchwartzSLGranthamSRMacLeanLKLeeSNPugh-TooleMet al. NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis. Transl Oncol (2021) 14(1):100930. doi: 10.1016/j.tranon.2020.100930

  • CrossRef
  • Google Scholar

• 74

  ZhangSLiuWHuBWangPLvXChenSet al. Prognostic significance of tumor-infiltrating natural killer cells in solid tumors: A systematic review and meta-analysis. Front Immunol (2020) 11:1242. doi: 10.3389/fimmu.2020.01242

  • CrossRef
  • Google Scholar

• 75

  LiuCLiXHuangQZhangMLeiTWangFet al. Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer. Signal Transduct Target Ther (2023) 8(1):44. doi: 10.1038/s41392-022-01264-9

  • CrossRef
  • Google Scholar

• 76

  ZinovkinDALyzikovaYANadyrovEAPetrenyovDRYuzugulenJPranjolMZI. Gamma-ray irradiation modulates PGRMC1 expression and the number of CD56+ and FoxP3+ cells in the tumor microenvironment of endometrial endometrioid adenocarcinoma. Radiat Oncol J (2021) 39(4):324–33. doi: 10.3857/roj.2021.00472

  • CrossRef
  • Google Scholar

• 77

  AlderdiceMDunnePDColeAJO’ReillyPGMcArtDGBinghamVet al. Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. Mod Pathol (2017) 30(9):1287–98. doi: 10.1038/modpathol.2017.47

  • CrossRef
  • Google Scholar

• 78

  SchaueDKachikwuELMcBrideWH. Cytokines in radiobiological responses: a review. Radiat Res (2012) 178(6):505–23. doi: 10.1667/RR3031.1

  • CrossRef
  • Google Scholar

• 79

  Vanpouille-BoxCDemariaSFormentiSCGalluzziL. Cytosolic DNA sensing in organismal tumor control. Cancer Cell (2018) 34(3):361–78. doi: 10.1016/j.ccell.2018.05.013

  • CrossRef
  • Google Scholar

• 80

  YamazakiTKirchmairASatoABuqueARybsteinMPetroniGet al. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nat Immunol (2020) 21(10):1160–71. doi: 10.1038/s41590-020-0751-0

  • CrossRef
  • Google Scholar

• 81

  FitzgeraldAAWangSAgarwalVMarcisakEFZuoAJablonskiSAet al. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. J Immunother Cancer (2021) 9(11):e002837. doi: 10.1136/jitc-2021-002837

  • CrossRef
  • Google Scholar

• 82

  WalleTKraskeJALiaoBLenoirBTimkeCvon Bohlen Und HalbachEet al. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Sci Adv (2022) 8(12):eabh4050. doi: 10.1126/sciadv.abh4050

  • CrossRef
  • Google Scholar

• 83

  YoonMSPhamCTPhanMTShinDJJangYYParkMHet al. Irradiation of breast cancer cells enhances CXCL16 ligand expression and induces the migration of natural killer cells expressing the CXCR6 receptor. Cytotherapy (2016) 18(12):1532–42. doi: 10.1016/j.jcyt.2016.08.006

  • CrossRef
  • Google Scholar

• 84

  KimJYSonYOParkSWBaeJHChungJSKimHHet al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med (2006) 38(5):474–84. doi: 10.1038/emm.2006.56

  • CrossRef
  • Google Scholar

• 85

  AmesECanterRJGrossenbacherSKMacSSmithRCMonjazebAMet al. Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells. Oncoimmunology (2015) 4(9):e1036212. doi: 10.1080/2162402X.2015.1036212

  • CrossRef
  • Google Scholar

• 86

  JeongJUUongTNTChungWKNamTKAhnSJSongJYet al. Effect of irradiation-induced intercellular adhesion molecule-1 expression on natural killer cell-mediated cytotoxicity toward human cancer cells. Cytotherapy (2018) 20(5):715–27. doi: 10.1016/j.jcyt.2018.01.010

  • CrossRef
  • Google Scholar

• 87

  KimKWJeongJULeeKHUongTNTRheeJHAhnSJet al. Combined NK cell therapy and radiation therapy exhibit long-term therapeutic and antimetastatic effects in a human triple negative breast cancer model. Int J Radiat Oncol Biol Phys (2020) 108(1):115–25. doi: 10.1016/j.ijrobp.2019.09.041

  • CrossRef
  • Google Scholar

• 88

  CanterRJGrossenbacherSKFoltzJASturgillIRParkJSLunaJIet al. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial. J Immunother Cancer (2017) 5(1):98. doi: 10.1186/s40425-017-0305-7

  • CrossRef
  • Google Scholar

• 89

  MakowskaALelabiNNothbaumCShenLBussonPTranTTBet al. Radiotherapy combined with PD-1 inhibition increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells. Cells (2021) 10(9):2458. doi: 10.3390/cells10092458

  • CrossRef
  • Google Scholar

• 90

  LiMXueSLTangXXuJChenSHanYet al. The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients. Sci Rep (2022) 12(1):378. doi: 10.1038/s41598-021-04296-3

  • CrossRef
  • Google Scholar

• 91

  SantinADHermonatPLRavaggiABelloneSRomanJPecorelliSet al. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys (2000) 48(4):997–1006. doi: 10.1016/s0360-3016(00)00769-0

  • CrossRef
  • Google Scholar

• 92

  SantinADBelloneSPalmieriMBossiniBDunnDRomanJJet al. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10. Int J Radiat Oncol Biol Phys (2002) 54(5):1345–55. doi: 10.1016/S0360-3016(02)03757-4

  • CrossRef
  • Google Scholar

• 93

  MuroyamaYNirschlTRKochelCMLopez-BujandaZTheodrosDMaoWet al. Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment. Cancer Immunol Res (2017) 5(11):992–1004. doi: 10.1158/2326-6066.CIR-17-0040

  • CrossRef
  • Google Scholar

• 94

  BeaufordSSKumariAGarnett-BensonC. Ionizing radiation modulates the phenotype and function of human CD4+ induced regulatory T cells. BMC Immunol (2020) 21(1):18. doi: 10.1186/s12865-020-00349-w

  • CrossRef
  • Google Scholar

• 95

  KachikwuELIwamotoKSLiaoYPDeMarcoJJAgazaryanNEconomouJSet al. Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys (2011) 81(4):1128–35. doi: 10.1016/j.ijrobp.2010.09.034

  • CrossRef
  • Google Scholar

• 96

  Pedroza-PachecoIMadrigalASaudemontA. Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. Cell Mol Immunol (2013) 10(3):222–9. doi: 10.1038/cmi.2013.2

  • CrossRef
  • Google Scholar

• 97

  RutihindaCHarounRSaidiNEOrdonezJPNaasriSLevesqueDet al. Inhibition of the CCR6-CCL20 axis prevents regulatory T cell recruitment and sensitizes head and neck squamous cell carcinoma to radiation therapy. Cancer Immunol Immunother (2023) 72(5):1089–102. doi: 10.1007/s00262-022-03313-2

  • CrossRef
  • Google Scholar

• 98

  PiperMVan CourtBMuellerAWatanabeSBickettTBhatiaSet al. Targeting treg-expressed STAT3 enhances NK-mediated surveillance of metastasis and improves therapeutic response in pancreatic adenocarcinoma. Clin Cancer Res (2022) 28(5):1013–26. doi: 10.1158/1078-0432.CCR-21-2767

  • CrossRef
  • Google Scholar

• 99

  MondiniMLoyherPLHamonPGerbe de ThoreMLavironMBerthelotKet al. CCR2-dependent recruitment of tregs and monocytes following radiotherapy is associated with TNFalpha-mediated resistance. Cancer Immunol Res (2019) 7(3):376–87. doi: 10.1158/2326-6066.CIR-18-0633

  • CrossRef
  • Google Scholar

• 100

  ConnollyKABeltBAFigueroaNMMurthyAPatelAKimMet al. Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes. Oncotarget (2016) 7(52):86522–35. doi: 10.18632/oncotarget.13287

  • CrossRef
  • Google Scholar

• 101

  KalbasiAKomarCTookerGMLiuMLeeJWGladneyWLet al. Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma. Clin Cancer Res (2017) 23(1):137–48. doi: 10.1158/1078-0432.CCR-16-0870

  • CrossRef
  • Google Scholar

• 102

  SantinADHermonatPLHiserodtJCChiriva-InternatiMWoodliffJTheusJWet al. Effects of irradiation on the expression of major histocompatibility complex class I antigen and adhesion costimulation molecules ICAM-1 in human cervical cancer. Int J Radiat Oncol Biol Phys (1997) 39(3):737–42. doi: 10.1016/S0360-3016(97)00372-6

  • CrossRef
  • Google Scholar

• 103

  AshrafizadehMFarhoodBEleojo MusaATaebSNajafiM. Damage-associated molecular patterns in tumor radiotherapy. Int Immunopharmacol (2020) 86:106761. doi: 10.1016/j.intimp.2020.106761

  • CrossRef
  • Google Scholar

• 104

  HerreraFGRonetCOchoa de OlzaMBarrasDCrespoIAndreattaMet al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov (2022) 12(1):108–33. doi: 10.1158/2159-8290.CD-21-0003

  • CrossRef
  • Google Scholar

• 105

  ParikhARSzabolcsAAllenJNClarkJWWoJYRaabeMet al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer (2021) 2(11):1124–35. doi: 10.1038/s43018-021-00269-7

  • CrossRef
  • Google Scholar

• 106

  SiaJHagekyriakouJChindrisIAlbarakatiHLeongTSchlenkerRet al. Regulatory T cells shape the differential impact of radiation dose-fractionation schedules on host innate and adaptive antitumor immune defenses. Int J Radiat Oncol Biol Phys (2021) 111(2):502–14. doi: 10.1016/j.ijrobp.2021.05.014

  • CrossRef
  • Google Scholar

• 107

  SchaueDRatikanJAIwamotoKSMcBrideWH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys (2012) 83(4):1306–10. doi: 10.1016/j.ijrobp.2011.09.049

  • CrossRef
  • Google Scholar

• 108

  PaganettiH. A review on lymphocyte radiosensitivity and its impact on radiotherapy. Front Oncol (2023) 13:1201500. doi: 10.3389/fonc.2023.1201500

  • CrossRef
  • Google Scholar

• 109

  CitrinDE. Recent developments in radiotherapy. N Engl J Med (2017) 377(11):1065–75. doi: 10.1056/NEJMra1608986

  • CrossRef
  • Google Scholar

• 110

  GattinoniLPowellDJJr.RosenbergSARestifoNP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 6(5):383–93. doi: 10.1038/nri1842

  • CrossRef
  • Google Scholar

• 111

  DudleyMEYangJCSherryRHughesMSRoyalRKammulaUet al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 26(32):5233–9. doi: 10.1200/JCO.2008.16.5449

  • CrossRef
  • Google Scholar

• 112

  YangGKongQWangGJinHZhouLYuDet al. Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy. Cancer Biother Radiopharm (2014) 29(10):428–34. doi: 10.1089/cbr.2014.1702

  • CrossRef
  • Google Scholar

• 113

  SonnCHChoiJRKimTJYuYBKimKShinSCet al. Augmentation of natural cytotoxicity by chronic low-dose ionizing radiation in murine natural killer cells primed by IL-2. J Radiat Res (2012) 53(6):823–9. doi: 10.1093/jrr/rrs037

  • CrossRef
  • Google Scholar

• 114

  ChedaAWrembel-WargockaJLisiakENowosielskaEMMarciniakMJaniakMK. Single low doses of X rays inhibit the development of experimental tumor metastases and trigger the activities of NK cells in mice. Radiat Res (2004) 161(3):335–40. doi: 10.1667/rr3123

  • CrossRef
  • Google Scholar

• 115

  JinSZPanXNWuNJinGHLiuSZ. Whole-body low dose irradiation promotes the efficacy of conventional radiotherapy for cancer and possible mechanisms. Dose Response (2007) 5(4):349–58. doi: 10.2203/dose-response.07-020.Jin

  • CrossRef
  • Google Scholar

• 116

  MulthoffGSeierSStanglSSievertWShevtsovMWernerCet al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: A randomized phase II clinical trial. Clin Cancer Res (2020) 26(20):5368–79. doi: 10.1158/1078-0432.CCR-20-1141

  • CrossRef
  • Google Scholar

• 117

  JinLTaoHKarachiALongYHouAYNaMet al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun (2019) 10(1):4016. doi: 10.1038/s41467-019-11869-4

  • CrossRef
  • Google Scholar

• 118

  NgYYTayJCKWangS. CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts. Mol Ther Oncolytics (2020) 16:75–85. doi: 10.1016/j.omto.2019.12.006

  • CrossRef
  • Google Scholar

• 119

  XiaoLCenDGanHSunYHuangNXiongHet al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol Ther (2019) 27(6):1114–25. doi: 10.1016/j.ymthe.2019.03.011

  • CrossRef
  • Google Scholar

• 120

  ZhangCRoderJSchererABoddenMPfeifer SerrahimaJBhattiAet al. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity. J Immunother Cancer (2021) 9(10):e002980. doi: 10.1136/jitc-2021-002980

  • CrossRef
  • Google Scholar